Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial
Latest Information Update: 22 Feb 2019
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FERRIC HF II
- 19 Feb 2019 Primary endpoint (Change in skeletal muscle oxidative capacity as assessed by PCr t1/2 from baseline to 2 weeks post last treatment.) has been met, according to the results published in the Circulation
- 19 Feb 2019 Results published in the Circulation
- 07 Jun 2017 Status changed from recruiting to completed.